Introduction

Methods

Results

Conclusions

LBA designation will only be given to impactful prospective studies that will change clinical practice within the year and whose data are not available at the time of regular abstract submission due to study events and/or timelines.

LBA designation is not a means for extending the regular abstract deadline. Highly impactful studies that have complete data should be submitted as a regular abstract and will be considered for a prominent oral presentation based on scoring by the program committee.

For abstracts that do not meet LBA requirements the authors will be given 5 business days to update the submitted data before the abstracts are re-classified as regular abstracts and rated based on the updated information.

Authors of LBA must submit an intent to submit an LBA abstract through the abstract portal by September 12, 2025 (23:59 PDT).

Explanation of why the abstract qualifies as late-breaking

Introduction

Methods, including applicable endpoints

Types of anticipated analysis and data to be reported

The Committee will review all submissions with the intent to submit LBA abstracts after the regular abstract submission deadline September 12, 2025. Authors of approved LBA applications will be notified and advised on the processes for submitting final data by October 10, 2025. Authors of abstracts not being accepted for LBA submissions will be notified and given 5 days to submit all available data before the abstract is re-classified as a regular abstract and included in the regular abstract review and scheduling process.

An encore abstract will only be considered if there have been significant updates to the presentation.

Submitters are required to list any previous presentations during the abstract submission process.